by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP and Mark Hamilton, MD, of The University of Texas MD Anderson Cancer Center discuss immune effector cell-associated...
by Frederick Locke
Our latest committee member spotlight features Frederick L. Locke, MD, chair of the Department of Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center and chair of...
by Molecular Therapy Advances
Scientists believe lentiviral (LV)-based virus-like particles (VLPs) could improve chimeric antigen receptor (CAR) T-cell therapies and enable rapid, scalable production of gene-edited CAR T-cells...
by Blood
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD70 has the potential to improve outcomes in individuals with follicular lymphoma (FL) who have elevated relapse risk.
by Transplantation and Cellular Therapy
Graft-versus-host disease (GVHD) and non-relapse mortality (NRM) are possible after allogeneic hematopoietic cell transplantation (allo-HCT), but researchers say a recipient's pre-procedure...
by British Journal of Haematology
Results from a retrospective investigation identified deletion (13q)/monosomy 13 (del[13q]/-13) as an independent risk factor for poor outcomes in multiple myeloma (MM) patients receiving upfront...